反応式
Cl[CH2:2][CH2:3][O:4][CH2:5][C:6]([OH:8])=[O:7].ClCCO[CH2:13][C:14]([NH2:16])=O.C(OO[CH2:22][CH2:23][Cl:24])(=O)C.ClCCO[CH2:29][C:30]#[N:31].C(=O)([O-])[O-].[Na+].[Na+].C(=O)([O-])[O-].[K+].[K+].[C:44]1([CH3:51])[C:45](C)=[CH:46][CH:47]=[CH:48][CH:49]=1>C1(C)C=CC=CC=1>[Cl:24][C:23]1[CH:22]=[CH:48][C:49]([CH:51]([C:44]2[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=2)[N:16]2[CH2:14][CH2:13][N:31]([CH2:2][CH2:3][O:4][CH2:5][C:6]([OH:8])=[O:7])[CH2:30][CH2:29]2)=[CH:44][CH:45]=1参加物
9
実験手順
The compound (I) may be further treated with a 2-chloroethoxy acetic acid derivative such as 2-chloroethoxy acetamide or 2-chloroethoxy acetate or 2-chloroethoxy acetonitrile in the presence of a base such as sodium carbonate or potassium carbonate, and a solvent such as toluene or xylene to obtain the corresponding [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid derivative which on hydrolysis, for example, using sodium hydroxide gives levocetirizine.
出典と根拠
- ORDレコード
- ord-0709d4e8829142cd93bbdf1360d5fbd2
- 出典データセット
- uspto-grants-2013_01
- 特許番号
- US08350031B2
関連ノート
読み込み中…